Meeting
2019 Gastrointestinal Cancers Symposium
COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).
Authors
James J. Lee
NRG Oncology, and University of Pittsburgh Medical Center Cancer Pavilion, Pittsburgh, PA
James J. Lee , Greg Yothers , Samuel A. Jacobs , Hanna Kelly Sanoff , Deirdre Jill Cohen , Katherine A Guthrie , Norah Lynn Henry , Patricia A. Ganz , Scott Kopetz , Peter C. Lucas , Carmen Joseph Allegra , Charles David Blanke , Norman Wolmark , Howard S. Hochster , Thomas J. George , Michael J. Overman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02997228
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr TPS728)
DOI
10.1200/JCO.2019.37.4_suppl.TPS728
Abstract #
TPS728
Poster Bd #
Q13
Abstract Disclosures
Similar Posters
First Author: James J. Lee
Poster
2020 Gastrointestinal Cancers Symposium
A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610).
First Author: Caio Max Sao Pedro Rocha Lima
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).
First Author: Michael J. Overman
First Author: Caio Max Sao Pedro Rocha Lima